Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.

Jonathan HeseltineJennifer AllisonSam WongKellati PrasadZhu-Chuen OongHelen WongAndrea LawNatalie CharnleyOmi ParikhTom WaddellShien Chow

Published in: Targeted oncology (2023)

These data suggest comparable activity of tivozanib with the pivotal trial data and other TKIs in a real-world population. Its tolerability positions tivozanib as an attractive first-line option for those unsuitable for combination therapies or unable to tolerate other TKIs.

Keyphrases

metastatic renal cell carcinoma
electronic health record
open label
big data
clinical trial
study protocol
phase iii
data analysis
cross sectional
double blind
machine learning